Brown-Forman missed Q1 sales estimates due to weak consumer spending and health trends like GLP-1 drug usage, though it beat EPS and maintained flat annual growth forecasts.
Pernod Ricard reported a 3.9% organic sales decline for fiscal 2026 due to weak demand in the U.S. and China, missing analyst expectations. The company trimmed its medium-term growth guidance while pr
Brown-Forman beat Q4 sales estimates on strong premium spirit demand but forecast flat 2027 growth, citing challenging macroeconomic conditions and cost cycles in the beverage alcohol sector.
Indian investigators allege Pernod Ricard concealed Scotch whisky import details to evade $314 million in back taxes. The company denies wrongdoing, facing potential penalties over $600 million in its
Brown-Forman shares fell 6% after merger talks with Pernod Ricard collapsed due to unmet terms, shifting investor focus to demand challenges and potential Sazerac bids.
Pernod Ricard confirmed the termination of merger negotiations with Brown-Forman, citing failed terms, while rival Sazerac remains a potential bidder.
Pernod Ricard's finance chief confirmed ongoing merger talks with U.S. rival Brown-Forman, while a competing $15 billion offer from Sazerac complicates the potential deal.
ChemBrief